Esmocard 2500 mg sol. perf. (pdr., à diluer) i.v. flac. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

esmocard 2500 mg sol. perf. (pdr., à diluer) i.v. flac.

orpha-devel handels und vertriebs gmbh - chlorhydrate d'esmolol 2500 mg - poudre pour solution à diluer pour perfusion - 2500 mg - chlorhydrate d'esmolol 2500 mg - esmolol

Sitagliptin / Metformin hydrochloride Sun Union européenne - français - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

ESMOCARD 2500 mg/10 ml, solution à diluer pour perfusion France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

esmocard 2500 mg/10 ml, solution à diluer pour perfusion

orpha devel handels & vertriebs gmbh - esmolol (chlorhydrate d') - solution - 2500 mg - composition pour 10 ml de solution à diluer pour perfusion > esmolol (chlorhydrate d') : 2500 mg - agents β-bloquants, sélectifs

Brevibloc 10 mg/ml sol. inj. i.v. flac. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

brevibloc 10 mg/ml sol. inj. i.v. flac.

baxter sa-nv - chlorhydrate d'esmolol 10 mg/ml - solution injectable - 10 mg/ml - chlorhydrate d'esmolol 10 mg/ml - esmolol

Brevibloc 10 mg/ml sol. perf. i.v. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

brevibloc 10 mg/ml sol. perf. i.v.

baxter sa-nv - chlorhydrate d'esmolol 10 mg/ml - solution pour perfusion - 10 mg/ml - chlorhydrate d'esmolol 10 mg/ml - esmolol

BREVIBLOC 2,5 g/10 ml, solution injectable à diluer (I.V.) France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

brevibloc 2,5 g/10 ml, solution injectable à diluer (i.v.)

baxter sas - esmolol (chlorhydrate d') - solution - 2,5 g - composition pour 10 ml > esmolol (chlorhydrate d') : 2,5 g - beta-bloquant

Sitagliptin / Metformin hydrochloride Mylan Union européenne - français - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vildagliptin / Metformin hydrochloride Accord Union européenne - français - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

BREVIBLOC 20 mg/ml, solution pour perfusion France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

brevibloc 20 mg/ml, solution pour perfusion

baxter sas - chlorhydrate d'esmolol - solution - 20 mg - composition pour 1 ml de solution pour perfusion > chlorhydrate d'esmolol : 20 mg - béta-bloquants sélectifs

Sitagliptin / Metformin hydrochloride Accord Union européenne - français - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.